Vol 69, No 1 (2018)
Original paper
Published online: 2017-12-21

open access

Page views 1628
Article views/downloads 1225
Get Citation

Connect on Social Media

Connect on Social Media

A preliminary study on the expression and clinical value of platelet-derived growth factor BB, hypoxia inducible factor-1α and C-C motif chemokine receptor-2 in peripheral blood during the pathogenesis of Graves’ disease

Ying Liu1, Jinglan Tang1, Qiaohong Hu1, Kefeng Lu1, Chunjie Hou1
Pubmed: 29319128
Endokrynol Pol 2018;69(1):9-15.

Abstract

Introduction: Platelet-derived growth factor BB (PDGF-BB) plays an important role in the development of GD (Graves’ disease). However, it is still unknown whether PDGF-BB is expressed in peripheral blood and whether the expression of PDGF-BB contributes to GD. We aim to study the expression of PDGF-BB, hypoxia inducible factor (HIF)-1α and C-C motif chemokine receptor (CCR)-2 in peripheral blood of patients with GD and explore its effect and potential mechanism in pathogenesis. Material and methods: 41 patients with GD (GD group) and forty-five healthy people (control group) were chosen. The concentration of PDGF-BB and HIF-1α in peripheral blood specimens were detected and compared between the two groups. The expression of CCR2 in macrophages in the peripheral blood specimens were examined using FCM (Flow Cytometry). Results: Both PDGF-BB and HIF-1α were expressed in human peripheral blood from the two groups. Compared with specimens from healthy people, there were statistically increased concentrations of PDGF-BB and HIF-1α in the GD group (P < 0.05). The proportion of CCR2-positive macrophages in peripheral blood in the GD group was significantly higher than that in the control group (P < 0.05). Conclusions: CCR2-positive macrophages may induce the expression of PDGF-BB through HIF-1α signal, and the high expression of PDGF-BB may be involved in the pathogenesis of GD.

Article available in PDF format

View PDF Download PDF file

References

  1. Andrae J, Gallini R, Betsholtz C. Role of platelet-derived growth factors in physiology and medicine. Genes Dev. 2008; 22(10): 1276–1312.
  2. Chen XS, Sun D, Yao X. Research Progress on PDGF/PDGFR in Cancer and Related Targeted Therapy. Chinese Journal of Clinical Oncology. 2012; 39: 1134–1137.
  3. Li Q, Ma LK. Role and Possible Mechanism of PDGF Signaling Pathways During Process of Myocardial Fibrosis Induced by Aldosterone. Advances in Cardiovascular Diseases. 2012; 33: 85–88.
  4. Liu HJ, Gao XZ, Jin Y, et al. Role of PDGFR-β signal pathway in morphine tolerance. Journal of Medical Postgraduates. 2015; 28: 149–152.
  5. Cheng P, Gao ZQ, Liu YH, et al. Platelet-derived growth factor BB promotes the migration of bone marrow-derived mesenchymal stem cells towards C6 glioma and up-regulates the expression of intracellular adhesion molecule-1. Neurosci Lett. 2009; 451(1): 52–56.
  6. Cheng J, Ye H, Liu Z, et al. Platelet-derived growth factor-BB accelerates prostate cancer growth by promoting the proliferation of mesenchymal stem cells. J Cell Biochem. 2013; 114(7): 1510–1518.
  7. Wang BL, Wang XR. Regulation of the hypoxia inducible factor-1α by the inflammatory mediators[J]. Inter J Pathol Clin Med. 2008; 90: 1673–1688.
  8. Yoshimura T, Robinson EA, Tanaka S, et al. Purification and am ino acid analysis of two human glioma-derived monocyte chemoattractants[ J] . J ExpMed. 1989; 169: 1449–1459.
  9. Lee EY, Chung CH, Khoury CC, et al. The monocyte chemoattractant protein-1/CCR2 loop, inducible by TGF-beta, increases podocyte motility and albumin permeability. Am J Physiol Renal Physiol. 2009; 297(1): F85–F94.
  10. Chen BY, Guan CN. The research progress of relationship between MCP-1 and HIF-1 and tumor angiogenesis. JMed Res. 2010; 39: 27–30.
  11. Chen SJ, Xu XJ, Huo X. Research Development about Relationship of PDGFs and its Receptor with Related Diseases. Medical Recapitulate. 2008; 14: 1441–1444.
  12. Qi L, Du J, Zhang Z, et al. Low differentiated microvascular density and low expression of platelet-derived growth factor-BB (PDGF-BB) predict distant metastasis and poor prognosis in clear cell renal cell carcinoma. BJU Int. 2013; 112(4): E415–E423.
  13. van Steensel L, Hooijkaas H, Paridaens D, et al. PDGF enhances orbital fibroblast responses to TSHR stimulating autoantibodies in Graves' ophthalmopathy patients. J Clin Endocrinol Metab. 2012; 97(6): E944–E953.
  14. Compile Group of Endocrinology branch of Chinese medical association. Chinese guidelines of diagnosis and treatment of thyroid diseases - Hyperthyroidism. Chinese Journal of Internal Medicine. 2007; 46: 876–882.
  15. Tang YG. Analysis of the clinical effect of methimazole combined with levothyroxine for treating hyperthyroid exophthalmos. Heilongjiang Medical Journal. 2016; 29: 279–280.
  16. Fang WZ, Luo ZW. Progress in Treatment of Graves Ophthalmopathy. Medical Recapitulate. 2014; 20: 3534–3536.
  17. Menconi F, Marcocci C, Marinò M. Diagnosis and classification of Graves' disease. Autoimmun Rev. 2014; 13(4-5): 398–402.
  18. Scholz CC, Taylor CT. Targeting the HIF pathway in inflammation and immunity. Curr Opin Pharmacol. 2013; 13(4): 646–653.
  19. Chen W, Hill H, Christie A, et al. Targeting renal cell carcinoma with a HIF-2 antagonist. Nature. 2016; 539(7627): 112–117.